Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$17.46 USD
-0.21 (-1.19%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $17.41 -0.05 (-0.29%) 6:18 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.46 USD
-0.21 (-1.19%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $17.41 -0.05 (-0.29%) 6:18 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
Teva (TEVA) Q3 Earnings Miss, Cuts 2017 View, Stock Falls
by Zacks Equity Research
Teva (TEVA) third quarter earnings missed estimates while revenues were in line. The company lowered its earnings and revenue guidance for 2017, for the second time this year.
Allergan (AGN) Tops Q3 Earnings Estimates, Tweaks 2017 View
by Zacks Equity Research
Allergan (AGN) beat expectations for earnings while delivering in-line revenues in Q3. While the company slightly lowered its sales guidance, it raised the upper end of the earnings guidance.
Is a Turnaround in Store for Teva (TEVA) in Q3 Earnings?
by Zacks Equity Research
Teva's (TEVA) generic segment may continue to see weakness due to significant competitive and pricing pressure in the U.S. generics industry, which will continue to hurt the top line.
Teva Submits BLA to FDA for Migraine Candidate Fremanezumab
by Zacks Equity Research
Teva Pharma (TEVA) submits BLA seeking approval for its pipeline candidate, Fremanezumab, as a preventive treatment for migraine in the United States.
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
by Zacks Equity Research
Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna
Pricing Pressure, Competition Remain Headwinds for Pharma Stocks
by Arpita Dutt
Although the pharma and biotech sectors have rebounded in 2017, drug companies may find it a bit difficult to justify their high prices.
Where to Find Value in Healthcare Stocks
by Tracey Ryniec
The Biotech stocks have been on a big run in 2017, but that doesn't mean there aren't some healthcare values still out there.
Allergan (AGN) Loses Restasis Patent Lawsuit, Shares Fall
by Zacks Equity Research
Allergan (AGN) lost a patent infringement lawsuit filed against companies trying to develop a generic version of its eye drug, Restasis, which is also its second bestselling drug.
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
by Zacks Equity Research
Zacks Industry Outlook Highlights: Gilead, Teva, Pfizer and Amgen
Pharma Industry Outlook - October 2017
by Arpita Dutt
New product sales ramping up, R&D success and innovation, strong results, a higher number of FDA approvals and continued strong performance from key products are some of the factors that could contribute to a sustained recovery in the sector.
Mylan Gets Complete Response Letter For Biosimilar Neulasta
by Zacks Equity Research
Mylan (MYL) suffered a setback following the FDA's CRL for the company's BLA for MYL-1401H, a proposed biosimilar of Neulasta.
Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute
by Zacks Equity Research
Lilly (LLY) has received a favorable ruling from the U.S. PTO in a dispute related to vitamin regimen patent on its key cancer drug, Alimta.
Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early
by Zacks Equity Research
Teva's (TEVA) shares plunged after Mylan announced an earlier-than-expected launch of its generic version of the 40-mg thrice-weekly formulation of its blockbuster multiple sclerosis drug, Copaxone.
Teva Shares Plummet After Mylan's Copaxone Generic Gets FDA Approval
by Ryan McQueeney
Shares of Teva Pharmaceuticals (TEVA) opened more than 13% lower on Wednesday, plunging close to their 52-week low in the process. The struggling Israeli pharma firm, which has faced significant pressure to reduce its debt load, is sliding once again--this time because of a brand new competitor.
Mylan (MYL) Gets FDA Approval for Generic Copaxone 40mg
by Zacks Equity Research
Mylan N.V. (MYL) gets a boost with the FDA's approval of the generic version of multiple sclerosis drug Copaxone.
Allergan's Botox Gets FDA Nod for Forehead Line Treatment
by Zacks Equity Research
Allergan (AGN) secures an FDA approval for Botox Cosmetic product for its third indication of forehead line development.
Allergan (AGN) Pipeline & New Drugs to Counter Generic Woes
by Zacks Equity Research
Allergan's key drugs like Botox/Linzess and new drugs are supporting sales. However, Allergan faces generic threat for Namenda franchise and patent challenges for some other branded drugs.
Teva Reintroduces Generic Depo-Provera Injection in U.S.
by Zacks Equity Research
Teva (TEVA) announced the reintroduction of the generic equivalent to Depo-Prover Contraceptive Injection 150 mg/mL in the United States.
Impax Generic Division Progresses Well Amid Pricing Pressure
by Zacks Equity Research
Impax Laboratories' (IPXL) generic portfolio has progressed well so far this year. Moreover, approval of the generic versions of Vytorin and Concerta is a positive.
Allergan Authorizes New $2B Share Buyback Plan, Stock Up
by Zacks Equity Research
Allergan plc (AZN) sanctions a new stock repurchase program. The company also reiterates its commitment toward annual hike of quarterly cash dividend.
Teva/Nuvelution to Speed Up Development of Austedo in US
by Zacks Equity Research
Teva Pharma (TEVA) and Nuvelution inked a deal to accelerate the development of Austedo (deutetrabenazine) tablets for the treatment of tics associated with Tourette syndrome.
Teva's Leukemia Drug sNDA Granted Priority Review by the FDA
by Zacks Equity Research
Teva Pharmaceutical's (TEVA) sNDA for label expansion of Trisenox as first-line treatment of acute promyelocytic leukemia has been accepted by the FDA under priority review.
Company News For Sep 13, 2017
by Zacks Equity Research
Companies in the news are: TEVA,WDC,AMZN,LMNR
Teva's New CEO Brings No Relief: Generic Drugmakers to Dump
by Zacks Equity Research
The New CEO appointment at Teva (TEVA has once again shifted focus to the Generic Drug industry, which is presently facing several challenges.
Company News For Sep 12, 2017
by Zacks Equity Research
Companies in the news are: TEVA,BMY,EFX,FB